Issue 6
What's next for mRNA after COVID-19, and will there be any CDMOs left?
Why not sign up for our future email newsletters? Sign up here.
Included in this issue:
LEAD STORY
What’s Next in mRNA After COVID-19?
The COVID-19 pandemic brought its fair share of disruption and uncertainty; propelling biopharma-related topics into the public consciousness. The development of mRNA vaccines took centre stage. Investigated as potential treatments since the 1990s, companies like Moderna and Pfizer/BioNTech gave them top billing. Though their time in the limelight was relatively short, the role that mRNA-based vaccines played in saving lives and nurturing the world back to normal has been widely acknowledged.
Read more here.
FEATURED STORIES
FDA Approves New PAH Treatments: OPSYNVI® and Winrevair
Read more here.
J&J Sues Ex-Employee Over Alleged Theft of Trade Secrets for Pfizer
Read more here.
Lilly Reinforces Chinese Market Commitment Amidst US-China Biotech Tensions
Read more here.
FDA Rejects Regeneron's Blood Cancer Therapy Odronextamab Pending More Data
Read more here.
Novo Nordisk Acquires Cardior Pharmaceuticals to Boost Cardiovascular Pipeline
Read more here.
Sanofi and Owkin Intensify AI Alliance to Revolutionize Immunology Drug Development
Read more here.
BioNTech Faces NIH Default Notice Over COVID-19 Vaccine Royalties
Read more here.
Moderna Broadens Horizon with Promising Trials for New Vaccines
Read more here.
Bora Completes Acquisition of US-Based Upsher-Smith
Read more here.
Illumina Nears Victory in ECJ Appeal Over Grail Merger and EU Fine
Read more here.
AZ Expands Oncology Reach with Fusion Acquisition
Read more here.
Bristol Myers Squibb Announces Layoffs at Mirati Following $5.8 Billion Acquisition
Read more here.
Amgen's MariTide Challenges Weight Loss Drug Market with Innovative Approach and Promising Early Results
Read more here.
Novo Holdings Joins Bidding War for India's Healthium Medtech, Heightening Competition
Read more here.
The World's Most Expensive Drug Offers Hope for MLD Patients
Read more here.